Navigation Links
BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009
Date:1/14/2009

one."

This randomized trial compares the treatment of cartilage lesions using BST-CarGel(R) applied following microfracture to treatment with microfracture alone. The trial is enrolling subjects aged 18 to 55 years of age with focal cartilage lesions less than 10 cm2 located on the femoral condyles of the knee. Subjects are further stratified by their lesion type, either characterized as acute (i.e. traumatic) or chronic (i.e. degenerative). The primary endpoint for this trial is cartilage repair at twelve months, defined by the quantity and quality of the repaired tissue as measured with quantitative magnetic resonance imaging (MRI). Secondary endpoints are safety and knee-related pain, stiffness and function as measured using the Western Ontario and McMaster Universities (WOMAC) osteoarthritis index questionnaire. Results from this study are intended to support marketing applications in Canada and Europe.

About BioSyntech

BioSyntech is a medical device company specialized in the development, manufacturing and commercialization of advanced biotherapeutic thermogels for regenerative medicine (tissue repair) and therapeutic delivery. BioSyntech's platform technology is a family of hydrogels called BST-Gel(R), some of which are liquid at low temperature and solid at human body temperature. These gels can be injected or applied to a specific local site and offer beneficial properties for the local repair of damaged tissue such as cartilage, bone and chronic wounds and provide the benefit of avoiding invasive surgery. For additional information, visit www.biosyntech.com.

Forward-Looking Statements

This press release contains forward-looking statements and information which are subject to material risks and uncertainties. Such statements are not historical facts and are based on the current expectations of management. You are cautioned that su
'/>"/>

SOURCE BioSyntech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
2. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
3. West Concludes Agreement with Nektar
4. Workforce Alliance Concludes Three-Year Biotech Training Program
5. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
6. Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R)
7. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
8. Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment
9. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Nanyang Technological University (NTU) signed the Memorandum of ... Scientific Research (CNRS) and the Thales Group of ... the three parties are meeting again in Singapore ... at NTU. , Located at the Research ... the latest in science and technology to develop ...
(Date:12/16/2009)... Cord Blood America, Inc. (OTC Bulletin Board: CBAI), ... ( http://www.cordblood-america.com ) focused on bringing the ... insurance policy, to families nationwide and internationally, said ... a total of $1.4 million so far in ... eliminated for the year now tops $10 million. ...
(Date:12/16/2009)... to Special Protocol Assessment with the Food ... 16 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... a global biopharmaceutical company focused on oncology ... by its partner Keryx Biopharmaceuticals Inc. ("Keryx") ... clinical trial for perifosine (KRX-0401), the Company,s ...
(Date:12/15/2009)... 15 Epeius Biotechnologies Corporation, an emerging ... gained international validation of the cutting-edge science behind ... scientists around the world rediscovered the Cyclin ... of cancer pathogenesis and disease progression, and thus ... at the NIH National Cancer Institute investigating the ...
Breaking Biology Technology:New Singapore-French nanotech lab opens at NTU 2New Singapore-French nanotech lab opens at NTU 3Cord Blood America Says 2009 Debt Reduction Tops $10 Million 2Cord Blood America Says 2009 Debt Reduction Tops $10 Million 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 4AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 5Scientists Rediscover Gene Target for Cancer Therapy 2Scientists Rediscover Gene Target for Cancer Therapy 3
... Despite the well-known dangers of first- and secondhand smoke, an ... smokers. Exposure of a developing baby to harmful cigarette ... each year and poses a significant health care burden. , ... of researchers has completed a global assessment of newborns, umbilical ...
... Support ConjuChem,s, R&D Efforts ... and BAGSVAERD, Denmark, Dec. 3 /PRNewswire-FirstCall/ - ConjuChem Biotechnologies ... of Novozymes A/S (LSE:NVZ) announced today that the Companies ... by which Novozymes Biopharma will exclusively supply its recombinant ...
... SIAL ),and SouthWest NanoTechnologies Inc. (SWeNT), ... that they have signed an agreement under,which Sigma-Aldrich ... and development community. , ... Sigma-Aldrich will exclusively,distribute research quantities of SWeNT(R) CG ...
Other Biology Technology:Cutting the cord to determine babies' health risk from toxic exposure 2Cutting the cord to determine babies' health risk from toxic exposure 3Cutting the cord to determine babies' health risk from toxic exposure 4ConjuChem and Novozymes Enter Long-Term Supply Agreement for Recombumin(R) use in PC-DAC(TM):Exendin-4 2ConjuChem and Novozymes Enter Long-Term Supply Agreement for Recombumin(R) use in PC-DAC(TM):Exendin-4 3Sigma-Aldrich Signs Agreement With SouthWest NanoTechnologies to Distribute SWeNT(R) Single-Wall Carbon Nanotubes 2Sigma-Aldrich Signs Agreement With SouthWest NanoTechnologies to Distribute SWeNT(R) Single-Wall Carbon Nanotubes 3
(Date:12/16/2009)... our planet for more than 4 billion years before ... as many eons more. That suggests they may have ... Aviv University bacteria expert Prof. Eshel Ben-Jacob of the ... grounded in the study of bacteria, presents compelling evidence ... people should not automatically opt for the swine flu ...
(Date:12/16/2009)... will lead the coordinating center for a consortium of ... stem cell research. Michael L. Terrin, M.D.,C.M.,M.P.H., professor of ... Heart, Lung and Blood Institute (NHLBI) to coordinate the ... be called the NHLBI Progenitor Cell Biology Consortium. The ... grant over seven years. , ...
(Date:12/16/2009)... 1 GestureTek Inc. today announced ... - a turnkey, portable, plug and play ... entertainment and touring promotions. GestureTek is the ... in camera-enabled gesture recognition technology for interactive ... for quality, the CUBE has TUV, CE, ...
Breaking Biology News(10 mins):Bacteria wouldn't opt for a swine flu shot 2Bacteria wouldn't opt for a swine flu shot 3University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 2University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 3GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 2GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 3Ochsner Health System Relies on Trend Micro Enterprise Security for Immediate Protection and Lower Complexity 52412 1Ochsner Health System Relies on Trend Micro Enterprise Security for Immediate Protection and Lower Complexity 52412 2Ochsner Health System Relies on Trend Micro Enterprise Security for Immediate Protection and Lower Complexity 52412 3National Leaders Examine Sex and Responsibility in New Book 52407 1National Leaders Examine Sex and Responsibility in New Book 52407 2National Leaders Examine Sex and Responsibility in New Book 52407 3Conference Hound Launches Dedicated Conference and Trade Show Search Engine 52405 1Conference Hound Launches Dedicated Conference and Trade Show Search Engine 52405 2
... forest products industry has been growing rapidly since ... U.S. economy annually. Examples of nontimber forest products ... medicinal and herbal products, and specialty floral and ... U.S.-grown herbs used to satisfy increasing consumer demand ...
... Barro Colorado Island in Panama, home of the Smithsonian ... been described as the best-studied piece of tropical real ... been a mecca for biologists for nearly 90 years, ... the jaguaruntil now. , Montclair State University zoologist ...
... -- Crop water use efficiency (WUE, or yield per ... productivity, can be improved through irrigation management and methods, ... maximum yields) and supplemental irrigation (irrigating to supplement precipitation ... decline). Thus, WUE is key for agricultural production with ...
Other Biology News:Decreasing deer damage 2Decreasing deer damage 3First jaguar photo taken at Smithsonian Research Station in Panama 2Crop models help increase yield per unit of water used 2
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
... Product Goat polyclonal to Cholesterol Oxidase ... Reactivity / Specificity Cross-reacts with bacteria. ... Background Information Cholesterol oxidases exist as ... and are implicated in bacterial pathogenesis. In ...
Phospho-PERK (Thr980) Antibody...
Goat polyclonal to BACE1 ( Abpromise for all tested applications). entrezGeneID: 23621 SwissProtID: P56817...
Biology Products: